What is BioCryst Pharmaceuticals's change in AP?

BioCryst Pharmaceuticals (BCRX) reported change in AP of -$60.4M in Q1 2026.

How has BioCryst Pharmaceuticals's change in AP changed year-over-year?

BioCryst Pharmaceuticals's change in AP decreased by 85.3% year-over-year, from -$32.59M to -$60.4M.

What is the long-term trend for BioCryst Pharmaceuticals's change in AP?

Over 2 years (2021 to 2025), BioCryst Pharmaceuticals's change in AP has grown at a 21.1% compound annual growth rate (CAGR), from $39.41M to $57.8M.

What does change in AP mean?

Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.

BioCryst Pharmaceuticals BCRX Change in AP

Change in AP at other companies

Ionis PharmaceuticalsIONS

-$3.1M+88.1%

ANI PharmaceuticalsANIP

$5.36M-3.4%

AnaptysBio, Inc.ANAB

-$17.82M+25.9%

BridgeBio PharmaBBIO

-$7.17M-141%

PVL

Palvella TherapeuticsPVLA

$851K-24.3%

Arrowhead ResearchARWR

$15.26M+397%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's change in AP?: BioCryst Pharmaceuticals (BCRX) reported change in AP of -$60.4M in Q1 2026.
How has BioCryst Pharmaceuticals's change in AP changed year-over-year?: BioCryst Pharmaceuticals's change in AP decreased by 85.3% year-over-year, from -$32.59M to -$60.4M.
What is the long-term trend for BioCryst Pharmaceuticals's change in AP?: Over 2 years (2021 to 2025), BioCryst Pharmaceuticals's change in AP has grown at a 21.1% compound annual growth rate (CAGR), from $39.41M to $57.8M.
What does change in AP mean?: Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.